<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829799</url>
  </required_header>
  <id_info>
    <org_study_id>IRB202002831 -A</org_study_id>
    <nct_id>NCT04829799</nct_id>
  </id_info>
  <brief_title>Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain</brief_title>
  <official_title>Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of intraoperative intracameral Omidria (Phenylephrine and Ketorolac&#xD;
      1.0%/0.3%) verses 1% Lidocaine on pain reduction during and after cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale to measure pain</measure>
    <time_frame>Day 1 of operation</time_frame>
    <description>Measurement of pain intensity by mean visual analog scale (VAS) pain scores from 0 (no pain) to 10 (extreme pain) during operation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Pain Reduction</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive intracameral 1% preservative-free lidocaine following paracentesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive Omidria (phenylephrine and ketorolac (1.0%/0.3%) added to the ophthalmic irrigating solution during the cataract extraction procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% preservative-free lidocaine</intervention_name>
    <description>Instillation of intracameral lidocaine after initial paracentesis incision.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine 1.0%/ Ketorolac 0.3%</intervention_name>
    <description>Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.</description>
    <arm_group_label>Study Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with a cataract in the surgical eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that have previously exhibited sensitivities to acetylsalicylic acid,&#xD;
             phenylacetic acid derivative, and other nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
          -  Those with a past medical history of asthma&#xD;
&#xD;
          -  Those systemically using opioids or nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  Those prescribed additional topical mydriatics, topical steroids, pilocarpine, or&#xD;
             prostaglandins in the week preceding surgery&#xD;
&#xD;
          -  Those with a history of alpha-1-adrenergic antagonist use&#xD;
&#xD;
          -  Those with excisional, intraocular surgery in the planned surgical eye in the&#xD;
             preceding year&#xD;
&#xD;
          -  Those with a history of iris damage&#xD;
&#xD;
          -  Those requiring iris expanding device or those with an acute or chronic uncontrolled&#xD;
             eye condition, or those unable to effectively remember surgery or complete the&#xD;
             post-operative assessment.&#xD;
&#xD;
          -  Additionally, individuals less than 21 will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Grieser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

